{'fraction_non_alphanumeric': 0.024595924104005622, 'fraction_numerical': 0.011243851018973999, 'mean_word_length': 5.059574468085106, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Combined therapies improve survival in aggressive prostate cancer

Cancer June 15, 2018 immunotherapy as well as various checkpoint inhibitors in combination with standard chemotherapy. “We have all the tools we need to cure the other leukemias— it’s just a matter of doing the studies,” Dr. Kantarjian says. “In AML, I think we could get some very significant improvements in the foreseeable future with these 3 parallel tracks.” Specifically, he points to the prospect of improvements in therapy for the disease guided by the decipherment of its molecular pathology. This work includes researching FLT3 inhibitors, IDH1/2 inhibitors, novel antibodies targeting CD33 and CD123, and venetoclax as an important BCL2 inhibitor. Dr. Kantarjian is known for his tenacity in pursuing drugs that originally did not appear promising. Inotuzumab is not the only drug that he continued to research when others had given up on it. He also developed clofarabine for pediatric ALL and decitabine (originally considered too toxic by European researchers) for myelodysplastic syndrome. For that drug, he and colleagues originated the concept of low-intensity epigenetic therapy to reduce toxicity. “Even when drug companies and leukemia experts give up on a concept, if you challenge the traditional thinking, you can make discoveries that people have missed out on or were not willing to invest in because of their own biases,” he says.